Literature DB >> 27528716

How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer.

Timothy J Robinson1, Samantha Thomas1, Michaela A Dinan1, Sanziana Roman1, Julie Ann Sosa1, Terry Hyslop2.   

Abstract

PURPOSE: Patients who undergo surgery for papillary thyroid cancer with only a limited lymph node examination are thought to be at risk for potentially harboring occult disease. However, this risk has not been objectively quantified and may have implications for subsequent management and surveillance.
METHODS: Data from the National Cancer Database (1998 to 2012) were used to characterize the distribution of nodal positivity of adult patients diagnosed with localized ≥ 1-cm papillary thyroid cancer who underwent thyroidectomy with one or more lymph nodes (LNs) examined. A β-binomial distribution was used to estimate the probability of occult nodal disease as a function of total number of LNs examined and pathologic tumor stage.
RESULTS: A total of 78,724 patients met study criteria; 38,653 patients had node-positive disease. The probability of falsely identifying a patient as node negative was estimated to be 53% for patients with a single node examined and decreased to less than 10% when more than six LNs were examined. To rule out occult nodal disease with 90% confidence, six, nine, and 18 nodes would need to be examined for patients with T1b, T2, and T3 disease, respectively. Sensitivity analyses limited to patients likely undergoing prophylactic central neck dissection resulted in three, four, and eight nodes needed to provide comparable adequacy of LN evaluation.
CONCLUSION: To our knowledge, our study provides the first empirically based estimates of occult nodal disease risk in patients after surgery for papillary thyroid cancer as a function of primary tumor stage and number of LNs examined. Our estimates provide an objective guideline for evaluating adequacy of LN yield for surgeons and pathologists in the treatment of papillary thyroid cancer, and especially intermediate-risk disease, for which use of adjuvant radioactive iodine and surveillance intensity are not currently standardized.
© 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2016        PMID: 27528716      PMCID: PMC6366339          DOI: 10.1200/JCO.2016.67.6437

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  30 in total

1.  Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.

Authors:  Jérôme Clerc; Frederik A Verburg; Anca M Avram; Luca Giovanella; Elif Hindié; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

2.  Thyroid cancer: Occult disease risks quantified.

Authors:  Peter Sidaway
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

3.  Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease?

Authors:  Maria F Bates; Marcos R Lamas; Reese W Randle; Kristin L Long; Susan C Pitt; David F Schneider; Rebecca S Sippel
Journal:  Surgery       Date:  2017-11-08       Impact factor: 3.982

4.  Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system.

Authors:  N Chereau; T O Oyekunle; A Zambeli-Ljepović; H S Kazaure; S A Roman; F Menegaux; J A Sosa
Journal:  Br J Surg       Date:  2019-04-23       Impact factor: 6.939

5.  How many lymph nodes are enough? Assessing the adequacy of lymph node yield for staging in favorable histology wilms tumor.

Authors:  Amanda F Saltzman; Derek E Smith; Dexiang Gao; Debashis Ghosh; Arya Amini; Jennifer H Aldrink; Roshni Dasgupta; Kenneth W Gow; Richard D Glick; Peter F Ehrlich; Nicholas G Cost
Journal:  J Pediatr Surg       Date:  2019-06-20       Impact factor: 2.545

6. 

Authors:  文 刘; 治中 董; 艳军 苏; 云海 马; 建明 张; 畅 刁; 军 钱; 若川 程
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

7.  Metastasis to lymph nodes at the contralateral entrance point to the recurrent laryngeal nerve in unilateral thyroid papillary carcinoma: a case report and literature review.

Authors:  Chenxi Tian; Yishen Zhao; Meiyu Yuan; Qingfeng Fu; Yantao Fu
Journal:  Gland Surg       Date:  2022-02

8.  Risk probability model for residual metastatic lymph node in patients with papillary thyroid microcarcinoma undergoing cervical central lymph node dissection.

Authors:  Wen Liu; Zhizhong Dong; Yanjun Su; Yunhai Ma; Jianming Zhang; Chang Diao; Jun Qian; Ruochuan Cheng
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

9.  Patient Report of Recurrent and Persistent Thyroid Cancer.

Authors:  Maria Papaleontiou; Josh M Evron; Nazanene H Esfandiari; David Reyes-Gastelum; Kevin C Ward; Ann S Hamilton; Francis Worden; Megan R Haymart
Journal:  Thyroid       Date:  2020-04-16       Impact factor: 6.568

10.  Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer.

Authors:  Moran Amit; Samantha Tam; Mongkol Boonsripitayanon; Maria E Cabanillas; Naifa L Busaidy; Elizabeth Gardner Grubbs; Stephen Y Lai; Neil D Gross; Erich M Sturgis; Mark E Zafereo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-02-01       Impact factor: 6.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.